We are live on ! Find out more
MRTX

Mirati Therapeutics, Inc. Common Stock

Delisted

MRTX was delisted on the 22nd of January, 2024.

68 hedge funds and large institutions have $350M invested in Mirati Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 18

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

15% less funds holding

Funds holding: 8068 (-12)

30% less capital invested

Capital invested by funds: $499M → $350M (-$150M)

80% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 15

Holders
68
Holders Change
-12
Holders Change %
-15%
% of All Funds
1.81%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
3
Increased
33
Reduced
18
Closed
15
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
QSS
76
Quantitative Systematic Strategies
Florida
-$393K -12,830 Closed
Balyasny Asset Management
77
Balyasny Asset Management
Illinois
-$253K -8,020 Closed
AllianceBernstein
78
AllianceBernstein
Tennessee
-$234K -7,400 Closed
CSS
79
Cubist Systematic Strategies
Connecticut
-$211K -6,667 Closed
Bank of America
80
Bank of America
North Carolina
-$112K -5,024 -100%
PG
81
PEAK6 Group
Illinois
-$98K -3,100 Closed
BNP Paribas Financial Markets
82
BNP Paribas Financial Markets
France
-$71.7K -2,268 Closed
PAM
83
Panagora Asset Management
Massachusetts
-$44K -1,390 Closed

MRTX Hedge Fund Activity: Q1 2016 in Review

68 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2016, worth a combined $350M — down 30% from $499M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of MRTX and 3 opened new positions — a net loss of 12 holders — while 18 trimmed existing stakes and 33 added.

The largest buyer was Aviva Holdings, adding an estimated $22.9M. The largest seller was Boxer Capital, cutting an estimated $28.3M.

  • 68 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2016, down from 80 in Q4 2015.
  • Funds reported $350M of Mirati Therapeutics, Inc. Common Stock stock for Q1 2016, down 30% quarter-over-quarter.
  • 3 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2016 and 15 closed out, a net change of -12 holders.
  • The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2016 was Aviva Holdings, an estimated $22.9M added.
  • The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2016 was Boxer Capital, an estimated $28.3M sold.

Based on aggregated 13F filings for Q1 2016.